Keele Z

Proactive Review of patients taking Opioid Medicines for persistent Pain led by Pharmacists in primary care Teams

Julie Ashworth,^{1,2} Nicola Cornwall,¹ Sarah A Harrisson,^{1,2} Charlotte Woodcock,¹ Elaine Nicholls,^{1,3} Libby Laing,⁴ Christian D Mallen,^{1,2} Toby Helliwell,^{1,2} Gillian Lancaster,¹ Anthony Avery,⁵ Roger Knaggs,^{6,7,8} Tamar Pincus,⁹ Clare Jinks,¹ on behalf of the PROMPPT team.


¹ School of Medicine, Keele University; ² Midlands Partnership University NHS Foundation Trust; ³ Keele Clinical Trials Unit; ⁴ Nottingham Clinical Trials Unit; ⁵ Centre for Academic Primary Care, University of Nottingham; ⁶ School of Pharmacy, University of Nottingham; ⁷ Pain Centre Versus Arthritis, University of Nottingham; ⁸ Primary Integrated Community Services, Nottingham; ⁹ School of Psychology, University of Southampton.

Contact: <u>j.ashworth@keele.ac.uk</u>

Introduction

In UK primary care, clinical pharmacists working in general practices ('practice pharmacists') play an increasing role in managing patients with long-term conditions and seem ideally placed to review patients who are prescribed opioids long-term for persistent non-cancer pain.


This study aimed to investigate the acceptability, credibility and feasibility of delivering a practice pharmacist-led intervention (PROMPPT review) that aims to support patients with persistent pain to safely reduce opioids, where appropriate, without increasing pain or pain-related interference.



The PROMPPT review and training were co-designed with stakeholders (patients and healthcare professionals), using a personbased approach combined with best practice guidance and theory.

Methods

- Non-randomised design, with mixed methods process evaluation
- Eligible patients, prescribed opioids for ≥ 6months, identified from electronic records in four general (GP) practices in the West and East Midlands were invited to participate in a questionnaire study.
- A representative sample of questionnaire study participants were invited for a PROMPPT review with the practice pharmacist
- With consent, n=8 PROMPPT reviews were audio-recorded to check fidelity of review delivery in accordance with the training.
- Following the review, participants were sent an Acceptability
 Questionnaire and invited to consent to contact about an interview.
- Semi-structured telephone interviews were conducted with n=15 patients, n=4 practice pharmacists and n=4 GPs.
- Qualitative analysis used a framework approach, drawing on the Theoretical Framework of Acceptability.



Results

- 148 eligible patients were recruited to the questionnaire study between 26 Nov 2020 and 20 Apr 2021
- 123 (83%) completed 3-month follow-up
- Of 88 participants invited, 80 (90.9%) attended a PROMPPT review
- Due to the COVID-19 pandemic, 78 (97.5%) PROMPPT reviews were conducted by telephone.

Of 50 participants who returned an Acceptability Questionnaire



Patients interviewed had mixed feelings before the review:



- Following the review, patients with a clear plan for follow-up felt reassured about making changes to their pain medicines.
- Conversely, if the onus was on patients to arrange follow-up, some were less satisfied and/or confused about the plan.
- Overall, patients, pharmacists and GPs interviewed felt PROMPPT reviews were a good idea and considered practice pharmacists appropriate to conduct them.
- Patients & pharmacists expressed strong preference for face-to-face consultations where possible.

Conclusion

FUNDED BY

- PROMPPT practice pharmacist-led pain reviews were acceptable to patients, practice pharmacists and GPs. Study findings were used to:
 - o Refine the PROMPPT review invitation and patient information, to reduce uncertainty and anxiety about the review.
- Revise the pharmacist training package.
- A cluster randomised controlled trial evaluating the clinical and cost-effectiveness of the PROMPPT review is underway.

